{
    "nct_id": "NCT04033419",
    "official_title": "Memantine for Prevention of Cognitive Decline During Adjuvant or Neoadjuvant Chemotherapy in Patients With Breast Cancer",
    "inclusion_criteria": "* Able to provide informed consent\n* At least 18 years of age\n* Able to speak English\n* Diagnosed with breast cancer, Stages I-III\n* Scheduled for adjuvant or neoadjuvant chemotherapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* A history of adverse reaction to memantine\n* Another cancer diagnosis with an estimated survival of less than five years\n* Previous chemotherapy exposure\n* Severe cognitive impairment, defined as Blessed Orientation Memory Concentration Test (BOMC) â‰¥ 11.\n* Pregnancy, confirmed by a negative pregnancy test within 30 days of study enrollment, or breastfeeding\n* Current alcohol or drug abuse",
    "miscellaneous_criteria": ""
}